Nobel-Winning Optogenetics Moves Closer to Blindness Treatment
Nobel-winning optogenetics is moving beyond laboratory research, with experimental therapies exploring vision restoration while Indian scientists use the technology to study pain, itch and behaviour.
The 2026 Nobel Prize in Physiology or Medicine has put optogenetics firmly in the spotlight. The technology, which allows scientists to control selected nerve cells using light, is now moving from laboratory experiments towards potential medical treatments.
Karl Deisseroth, Peter Hegemann and Georg Nagel received the prize for discoveries that helped establish the field. Researchers can genetically modify specific neurons so they produce light-sensitive proteins, allowing their activity to be switched on or off with precisely timed light.
One of the most advanced clinical applications is retinal degeneration. Experimental therapies are attempting to make surviving retinal cells respond to light after diseases such as retinitis pigmentosa destroy photoreceptors. Trials of treatments including MCO-010 are investigating whether this approach can improve vision.
India is also part of the research story. Scientists at the Indian Institute of Science have used optogenetics in mice to investigate neural circuits linked to pain, stress, itch and behaviour. Other Indian institutions are exploring therapeutic applications.
However, brain-based treatments face major hurdles, including safe gene delivery, reaching precise neurons, delivering light deep into tissue and establishing long-term safety.
For now, optogenetics remains experimental. But a technology once confined largely to neuroscience labs is steadily inching towards the clinic—one carefully targeted beam of light at a time.
